BHI Therapeutic Sciences is initiating FDA endorsed Investigator-led IND (Investigational New Drug) clinical study of an FDA-approved cell therapy (Hematopoietic Progenitor Cell (HPC), cord blood) for treatment of acute ischemic stroke in NJ. This prospective, open-label, single-center, exploratory clinical study is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke. BHI Therapeutic Sciences is in the process of preparation of Investigator-led IND application to allow for initiation of a clinical study of an FDA-approved cell therapy (HPC, cord blood) for treatment of osteoarthritis. This prospective, open-label, single-center, exploratory clinical study will be designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intra-articular injection, in subjects with osteoarthritis.
BHI Therapeutic Sciences is bringing the miracle of life saving stem cell treatments to the world, and you can help. Thanks to new laws that allow anyone in the general public to invest in new and emerging companies, you can invest in BHI Therapeutic Sciences. Sign up here and be among the first to know of developments with stem cell therapy and the opening of our clinic in Texas.